Company Overview
NewGenIvf Group Limited operates as an investment holding company focused on providing assisted reproductive services to couples and individuals seeking fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company's business model encompasses a range of fertility treatment solutions, including in vitro fertilization, positioning it within the specialized medical care sector. It currently employs 76 individuals to support its operations across these international locations. With a market capitalization of $1.06M and annual revenue of $4.58M, the company represents a micro-cap entity in the Healthcare industry, specifically under the Medical Care Facilities classification. These valuation metrics indicate that the firm functions as a small-scale operator within a broader healthcare landscape, where the market cap significantly trails the $4.58M in revenue, suggesting a high valuation discount relative to its top-line performance.
Financial Health
The company reported revenue of $4.58M and net income of $17.44M for the trailing twelve months, while recording an EBITDA of $-6,801,572. The substantial gap between the positive net income of $17.44M and the negative EBITDA of $-6,801,572 reveals a highly unusual cost structure where non-operating income or one-time gains likely drove the bottom line, masking underlying operational losses. Free cash flow stands at $-8,526,913, indicating that the company is currently burning cash and lacks immediate financial flexibility to fund operations without external capital injections. Profitability metrics display extreme volatility, with a gross margin of 21.2%, an operating margin of -195.9%, and a profit margin of 381.2%. The negative operating margin suggests that operating expenses are significantly higher than gross profit, whereas the positive profit margin implies non-operating income is sufficient to generate overall net income. On the balance sheet, cash holdings of $3.15M are lower than the total debt of $5.50M, resulting in a debt-to-equity ratio of 19.15. This leverage profile indicates a highly leveraged position where debt obligations exceed available liquid assets. The current ratio is 3.43, which indicates that the company holds 3.43 times more current assets than current liabilities, suggesting adequate short-term liquidity despite the negative free cash flow. Return on equity stands at 160.5% while return on assets is -23.1%, revealing a divergence where shareholder equity is being expanded by non-operating gains rather than core asset efficiency.
Valuation Assessment
Valuation multiples for NewGenIvf Group Limited show a trailing P/E ratio of 0.00 and a forward P/E of 0.02. The difference between a zero trailing P/E and a minimal forward P/E of 0.02 implies that the market expects earnings to normalize from a position of zero or near-zero profitability, though the current earnings are technically positive due to non-operating factors. The price-to-book ratio is 0.00, indicating that the market values the company at zero times its book value, which suggests the stock is priced significantly below the accounting value of its net assets. Alternative valuation metrics further illustrate this disconnect, with a price-to-sales ratio of 0.23 and an EV/EBITDA of -0.26. These metrics suggest that investors are pricing the stock based on sales volume rather than earnings power, as the negative EV/EBITDA reflects the company's negative earnings before interest, taxes, and amortization. The 52-week high is $4440.00 and the 52-week low is $1.52. Given the market cap of $1.06M and the extreme range between $4440.00 and $1.52, the current trading price sits near the lower bound of this historical range, reflecting the disparity between the company's small market cap and its potential volatility. The beta is 0.00, which means the stock's price volatility is statistically uncorrelated with the broader market movements, presenting a unique risk profile for portfolio diversification.
Growth & Income
Revenue growth year-over-year is -12.9%, while earnings growth is N/A. The absence of a defined earnings growth rate, combined with negative revenue growth, implies that the company is contracting in terms of top-line activity and has not yet achieved a sustainable earnings expansion trajectory. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%. This structure indicates that the company retains all earnings and cash flows to reinvest into growth initiatives or to service its debt obligations rather than distributing income to shareholders. The overall growth and income profile is characterized by declining revenue, negative free cash flow, and a complete absence of dividend distributions, reflecting a phase of operational restructuring or significant investment in the business model.